Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6115909 | Diagnostic Microbiology and Infectious Disease | 2014 | 4 Pages |
Abstract
In a pneumococcal pneumonia murine model following influenza virus infection, garenoxacin was more effective than other fluoroquinolones and demonstrated high levels of bacterial eradication in the lung, low mortality, and potent histopathological improvements. Garenoxacin could potentially be used for the treatment of secondary pneumococcal pneumonia following influenza.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Yoshiko Fukuda, Yuri Furuya, Yusuke Nozaki, Masahiro Takahata, Nobuhiko Nomura, Junichi Mitsuyama,